PubMed Health⌕ Search

Biomedical subjects

Yan-qun Na

Publications and source records attributed to Yan-qun Na.

At least 19 recordsLinked to original sources
PubMed2006

Natural history of benign prostate hyperplasia.

BACKGROUND: Benign prostate hyperplasia is one of the most common diseases affecting the health of the aging males. Watchful waiting is an acceptable management strategy for benign prostate hyperplasia in which the patient is monitored by the physician but receives no active intervention. The epidemiological data on this are lacking in China. Our study was designed to evaluate the changes of signs and symptoms of patients with benign prostate hyperplasia during management by watchful waiting in China. METHODS: One hundred and forty-five patients with benign prostate hyperplasia aged > 50 years were enrolled in management by watchful waiting. All the patients were visited every 6 months and were given an International Prostate Symptom Score and Quality of Life questionnaire to complete. They also had uroflowmetry and were assessed using ultrasonography to get the volume of prostate, transition zone and amount of residual urine. The Student's t test, the Chi-square test, and variance analysis were used in the statistical analysis. RESULTS: All patients were visited after 6 months, the mean volume of transitional zone was found to have increased by 1.6 ml (P < 0.01), International Prostate Symptom Score was increased by 0.8 (P < 0.01) and Quality of Life was increased by 0.2 (P < 0.01), and there was no statistical change in other data. Among these patients, 17.9% (26/145) visited again after 12 months when the data failed to show a statistically significant difference among the three groups (0, 6, and 12 months). CONCLUSIONS: After one year's follow-up, the progression of benign prostate hyperplasia was slow and the clinical data did not undergo much change.

Aged↗
PubMed2006

[Expression of nucleosomal binding protein 1 in normal prostate benign prostate hyperplasia, and prostate cancer and significance thereof].

OBJECTIVE: To investigate the expression of nucleosomal binding protein 1 (NSBP1) in normal prostate (NP), benign prostate hyperplasia (BPH), and prostate cancer (PCa) and significance thereof. METHODS: Western blotting was used to detect the expression of NSBP1 in 10 specimens of NP from voluntary donors who died of accidents, and 15 specimens of PCa resected during operation. Immunohistochemistry was used to detect the NSBP1 expression in 19 specimens of NP resected during complete cystectomy from patients with bladder carcinoma, and 26 specimens of BPH and 40 specimens of PCa, all resected during operation. RESULTS: Western blotting showed that the relative optical density (OD) of NSBP1 in the PCa tissue was 0.66 +/- 0.02, significantly higher than that of the NP tissue (0.26 +/- 0.03, t = 37.308, P < 0.01). Immunohistochemistry showed that the positive and weak positive rates of protein expression of NSBP1 in the PCa tissue was 80.0% (32/40), significantly higher than those of the NP tissue (36.8%, 7/19) and BPH (34.6%, 9/26) (t = -3.569 and t = -4.152, both P < 0.01). The NSBP1 expression level in the PCa tissue was not correlated with the pathological staging, grade, and serum prostate-specific antigen (P = 0.911, 0.666, and 0.779). CONCLUSION: Highly expressed in the PCa tissue, NSBP1 protein is may be involved in the carcinogenesis of PCa.

Adult↗
PubMed2006

[Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].

OBJECTIVE: To investigate the protein expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter protein 1 (Glut-1) in renal cancer and bladder cancers and the clinical significance thereof. METHODS: TransAMTMELISA was used to detect the protein expression of HIF-1alpha in the tissue sections from 25 patients with bladder transitional cell carcinoma (TCC) and 16 patients with renal clear cell carcinoma resected during operation and small amounts of normal renal and bladder tissues far from the cancer tissue resected simultaneously. Immunohistochemistry was used to detect the protein expression of Glut-1 in tissue sections from 58 patients with bladder carcinoma transitional cell carcinoma and 38 patients with renal clear cell carcinoma resected during operation. 16 specimens of normal bladder and 16 specimens of normal renal tissue were obtained from the patients with other diseases who underwent operation during the same period to be used as controls. Follow-up was conducted for more than 2 years for all patients. RESULTS: The protein expression of HIF-1alpha in the tissue of renal clear cell carcinoma was 3.38 +/- 1.71 microg/well, significantly higher than that in the tissue near the cancer (2.23 +/- 1.07 microg/well, P < 0.01). The protein expression of HIF-1alpha in the bladder TCC tissue was 2.69 +/- 1.34 microg/well, not significantly different from that in the tissue near the cancer (248 +/- 1.28 microg/well, P = 0.60). Protein expression of Glut-1 was not detected in the normal renal and bladder tissues, however, was significantly higher in the bladder TCC and renal clear cell carcinoma tissues. The positive rate of Glut-1 in the bladder TCC tissue was 77.90% (45/58). The positive rates of Glut-1 in the tissues of bladder TCC tissue, grades G1, G2, and G3 were 66.7%, 89.1%, and 53.3%. (P = 0.29), showing the correlation of Glut-1 expression with the grading of cancer. The positive rate of Glut-1 in the superficial TCC was 83.9%, not significantly different from that of the invasive TVV (70.4%, P = 0.90), showing that the Glut-1 is not correlated with the cancer staging. Nineteen of the 31 cases of superficial TCC showed recurrence within 2 years, however, the protein expression of Glut-1 rate was not significantly different between those with recurrence and those without recurrence (P = 0.90), showing that the protein expression of Glut-1 is not correlated with the recurrence of TCC. The protein expression of Glut-1 in the renal clear cell carcinoma was at a rate of 86.9% (33/38), however, it was not correlated with the grade and stage of the cancer. CONCLUSION: The protein expression of HIF-1alpha is strongly associated with the neoplastic progression of renal clear cell carcinoma, but its role in the development of bladder TCC is not clear yet. The protein expression of Glut-1 is strongly associated with the neoplastic progression of bladder TCC and renal clear cell carcinoma.

Adult↗
PubMed2006

[Adriamycin and mitomycin dose-dependently downregulate X-kinked inhibitor of apoptosis protein in human bladder cancer cells].

OBJECTIVE: To investigate the efficacy of inducing apoptosis in human bladder cancer cells by adriamycin and mitomycin and relevant mechanism. METHODS: Human bladder cancer cells of the lines RT4, MGH-U1, FJ, and T24 were cultured. Adriamycin of the concentrations of 0.1, 1, and 10 microg/ml, and mitomycin of the concentrations of 0.01, 0.1, and 1 microg/ml were added into the culture fluid respectively. CCK-8 colorimetric assay was used to detect the survival rates of the cells so as to select the cell line sensitive and tolerable to the drugs. Flow cytometry was used to detect the cell apoptosis. Western blotting was used to detect the levels of X-kinked inhibitor of apoptosis protein (XIAP) and the cleavage of caspase-3 precursor. RESULTS: It was found that RT4 cells were the most sensitive and the T24 cells were the most tolerable to adriamycin and mitomycin. Treated with adriamycin of the concentrations of 0.1, 1, and 10 microg/ml for 24 hours, the apoptotic rates of the RT4 cells were 15.3% +/- 4.3%, 29.3% +/- 6.4%, and 45.0% +/- 5.5% respectively; and the apoptotic rates of the T24 cells were 7.3% +/- 3.1%, 12.5% +/- 4.3%, and 18.2% +/- 6.3% respectively, all significantly lower than those of the RT4 cells (P < 0.05 or P < 0.01). Treated with mitomycin of the concentrations of 0.01, 0.1, and 1 microg/ml for 24 hours, the apoptotic rates of the RT4 cells were 12.7% +/- 2.9%, 31.3% +/- 4.4%, and 48.9% +/- 5.8% respectively, and the apoptotic rates of the RT4 cells were 7.2% +/- 3.3%, 15.5% +/- 5.2%, and 21.2% +/- 4.4% respectively, all significantly lower than those of the RT4 cells (all P < 0.05). The XIAP expression was not significantly different in these 4 cell lines before the adriamycin and mitomycin treatment. After the treatment of adriamycin and mitomycin, the expression of XIAP was down-regulated dose-dependently, however, being weaker in the T24 cells than in the RT4 cells; and caspase-3 precursor cleavage was enhanced, however, being weaker in the T24 cells too. CONCLUSION: Adriamycin and mitomycin dose-dependently kill the human bladder cancer cells. Such cytotoxic effect may be realized through inducing the cell apoptosis which is associated with the down-regulation of XIAP and cleavage of caspase-3 precursor.

Antibiotics, Antineoplastic↗
PubMed2006

[Outcome of surgical management of renal cell carcinoma with renal vein or inferior vena cava tumor thrombus].

OBJECTIVE: To investigate the prognosis of surgical treatment for renal cell carcinoma with renal vein or inferior vena cava tumor thrombus. METHODS: Between August 1994 and July 2004, 33 patients with renal cell carcinoma with renal vein or inferior vena cava tumor thrombus underwent radical nephrectomy and thrombectomy. The study population included 26 male and 7 female. The median age was 60 years (20 - 82). Level of tumor thrombus was renal vein in 15 patients, infrahepatic (level I) in 9, intrahepatic (level II) in 5, suprahepatic (level III) in 1, and right atrial extension (level IV) in 3. Survival analysis was made with Kaplan-Meier method. RESULTS: Twenty-nine patients can be followed up. Fourteen patients were lost with a mean survival time of (16.4 +/- 2.9) months (1 - 42 months). Fifteen patients were survival with a mean follow-up of (17.3 +/- 4.6) months (3 - 67 months). One patient was lost on the second postoperative day. Three patients can not be followed up. The 5-year Kaplan-Meier survival rate was 16%. The mean survival time of patients with renal vein involvement [(49.9 +/- 9.8) months] versus level I [(16.7 +/- 1.9) months] was significantly different (P < 0.05). CONCLUSIONS: Radical nephrectomy plus thrombectomy is a valuable method for the treatment of renal cell carcinoma with renal vein or inferior vena cava involvement. Patients with renal vein tumor thrombus appear to have better survival compared to patients with inferior vena cava tumor thrombus.

Adult↗
PubMed2006

[The study of relationship between nuclear metrix protein 22 urinary level and the grade and stage of bladder transitional cell carcinoma].

OBJECTIVE: To assess the relationship between nuclear matrix protein (NMP) 22 urinary level and the grade and stage of bladder transitional cell carcinoma. METHODS: From June 1999 to March 2005 642 patients underwent NMP22 test, and then the test by cystoscope and pathology were performed in 1 week to 1 month. According to the pathological grade, the patients were divided into 3 groups: group G(1): 69 cases, male 58 and female 11; group G(2): 375 cases, male 255 and female 120; group G(3): 198 cases, male 143 and female 55. And the difference of NMP22 between each group were compared. Meanwhile, according to pathological stage, 239 patients were divided into 3 groups: group PT(1): 121 cases, male 76 and female 45; group PT(2): 65 cases, male 37 and female 28; group PT(3): 53 cases, male 29 and female 24. And the difference of NMP22 between each group were compared. RESULTS: The concentrations of NMP22 had significant difference between the 3 groups which divided according to pathological grade (Kruskal-Wallis test chi(2) = 67.547, P < 0.001); The concentrations of NMP22 had significant difference between the 3 groups which divided according to pathological stage (Kruskal-Wallis test chi(2) = 20.629, P < 0.001). CONCLUSIONS: There is a relation between NMP22 urinary level and the grade and stage of bladder transitional cell carcinoma.

Adolescent↗
PubMed2006

[Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score].

OBJECTIVE: To explore the method of predicting the stage of prostate cancer with serum prostate-specific antigen (PSA) and pathological grade. METHODS: One hundred and eighty-seven patients were studied retrospectively with prostate cancer diagnosed by systemic biopsy in our hospital. The rank correlation analysis, rank sum test and stepwise discriminant multivariate analysis were used to assess the correlation of serum PSA level, ratio of free PSA to total PSA (FPSA/TPSA ratio) with Gleason score (GS) and stage. RESULTS: Serum PSA level increased with GS for prostate cancer patients (r = 0.369, P < 0.001). With increasing stage, serum PSA level and GS increased (r = 0.398, 0.530, P < 0.001). Overall, FPSA/TPSA ratio was not correlated with stage (P > 0.70), but a significant negative correlation was demonstrated between them when serum PSA < or = 10 microg/L (r = -0.600, P < 0.05). When serum PSA > 20 microg/L, 67% - 87% patients with prostate cancer may be stage C or D. The equation using serum PSA and GS to predict the stage of patients with prostate cancer was: x = -3.488 + 0.041 x PSA + 0.428 x GS. CONCLUSIONS: Serum PSA level is positively correlated with GS for prostate cancer patients. Serum PSA level and GS are positively correlated with stage. A negative correlation between FPSA/TPSA ratio and stage is demonstrated when serum PSA < or = 10 microg/L. The combination of serum PSA and GS may predict the stage of patients with prostate cancer.

Adult↗
PubMed2006

[Clinical application of alpha1 adrenoceptor antagonist Naftopidil to the treatment of chronic non-bacterial prostatitis].

OBJECTIVE: To study the efficacy and safety of alpha1 adrenoceptor antagonist Naftopidil in the treatment of chronic non-bacterial prostatitis. METHODS: An opened, self-controlled, multicentral clinical trial was conducted. One hundred and six cases of patients who had been diagnosed as chronic non-bacterial prostatitis (NBP) were treated with Naftopidil (25 mg once a day) for 4 weeks. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the WBC in the examination of prostatic secretion (EPS) after the treatment. RESULTS: After 4 weeks therapy, 105 cases were evaluable. After treatment, NIH-CPSI total score were averagely decreased 12.0 points (P <0.001), symptom score 7.9 points (P <0.001) and QOL score 4.1 points (P <0.001). There was a statistically significant difference in WBC count ([(15.2 +/- 15.1)/HP vs (9.5 +/- 12.0)/HP, P < 0.01] and max flow rate(MFR) [(19.2 +/- 4.8) ml/s vs (22.7 +/- 4.9) ml/s, P < 0.01]. The total effective rate were 84.8% in the whole group. The clinical adverse rate was 3.81%, including 3 cases of mild dizziness and 1 case of mild inappetence. CONCLUSION: alpha1 adrenoceptor antagonist Naftopidil is effective and safe for the treatment of chronic non-bacterial prostatitis.

Adolescent↗
PubMed2006

[Effect and safety of transrectal 137 CS gamma-rays in the treatment of benign prostatic hyperplasia].

OBJECTIVE: To evaluate the effect and safety of transrectal 137Cs gamma-ray therapy for benign prostatic hyperplasia. METHODS: Thirty cases of BPH were treated by transrectal 137Cs gamma-rays. RESULTS: After 6 months there was significant improvement in the maximum urine flow, IPSS and QOL (P < 0.05). But no significant changes were observed in the prostate volume and residual urine (P > 0.05). CONCLUSION: Transrectal 137Cs gamma-ray therapy is safe and effective in the treatment of BPH.

Aged↗
PubMed2006

[A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis].

OBJECTIVE: To evaluate the efficacy and safety of Prostate in combination with an antibiotic for the treatment of chronic nonbacterial prostatitis. METHODS: A double-blind, parallel contrasted, multi-central method was applied in the study. After the Stamey test and expressed prostate secretion (EPS) examination, 160 patients with prostatitis were recruited and randomized into a trial group (80 cases with 1 case missing) and a control group (80 cases). In the trial group, the patients used the levofloxacin and Prostate during the first 4 weeks and Prostate only during the following 4 weeks. In the control group, the patients used the levofloxacin and placebo during the first 4 weeks, and placebo only during the following 4 weeks. Before and 4 and 8 weeks after the treatment, the patients were visited and evaluated by the national institute health-chronic prostatitis symptom index (NIH-CPSI), EPS, and asked about the side. RESULTS: After 4-week and 8-week treatment, the pain index dropped by 3.34 +/- 2.45 and 4.06 +/- 3.03 in the trial group, and effects. 2.28 +/- 2.42 and 3.30 +/- 3.29 in the control; the voiding index dropped by 2.22 +/- 1.79 and 2.77 +/- 2.04 in the trial group, and 1.24 +/- 1.67 and 1.83 +/- 2.25 in the control respectively. There was significant difference between pre-treatment and post-treatment in both the two groups (P < 0.01), while the difference was not significant between 4-week and 8-week post-treatment (P > 0.05). And there was significant difference between the two groups in the pain index and voiding index (P < 0.01), but not in the white blood cell count and lipid in the EPS (P > 0.05). No serious side effects were recorded, and the tolerance to Prostate and placebo showed no significant difference. CONCLUSION: Prostate in combination with an antibiotic can effectively relieve the pain and voiding symptoms and improve the life quality of the patients with nonbacterial prostatitis and well deserves to be recommended in clinical practice.

Adult↗
PubMed2006

[Aildenafil citrate: a new potent and highly selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction].

OBJECTIVE: To evaluate the efficacy and safety of aildenafil citrate, an oral phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction. METHODS: Integrated analyses were made of 8-week, randomized, double-blind, placebo-controlled phase 2 clinical trials involving 250 men with mild-to-severe erectile dysfunction of various etiologies who received aildenafil citrate 30 or 60 mg (n = 167) or placebo (n = 83). RESULTS: The statistic results of International Index of Erectile Function, Patient Sexual Encounter Profile (SEP) diaries and Global Assessment Question (GAQ) were significantly higher in the aildenafil citrate patients than in the placebo controls. The main drug-related adverse events were flushing, headache, dizziness and naupathia, which were mild and could be self-relieved. CONCLUSION: The aildenafil citrate therapy significantly ameliorated erectile function and was well tolerated by a wide range of patients with erectile dysfunction.

Administration, Oral↗
PubMed2006

[Treatment and prognosis of scrotal extramammary Paget's disease: a report of 23 cases].

OBJECTIVE: To evaluate the clinical manifestation, management and prognostic characteristics of scrotal extramammary Pagets disease (EMPD). METHODS: Twenty-three cases of EMPD were identified and retrospectively reviewed, and the clinical findings, surgical treatment, pathologic features and prognostic characteristics were evaluated. The patients ranged in age from 49 to 72 years (mean 62. 4 years). The diagnoses were delayed by 12 to 132 months (67. 6 on average) in 9 cases at Stage A1 , 12 at A2, 1 at B and 1 at D. The rate of initial misdiagnosis was 91.3% (21/23). Twenty of the patients underwent operations, 2 received radiotherapy and 1 chemotherapy. RESULTS: Twenty-two patients of the total number were followed up for 7 to 223 months, averaging at 119, therapy and 1 chemotherapy. of whom 12 remained cancer free, 1 died of tumor, 3 died of intercurrent disease, 4 experienced local recurrence, 1 relapsed with inguinal lymph node metastasis and 1 developed inguinal lymph node metastasis exclusively. Those with relapses received the second surgery, and 5 of them survived without cancer and 1 died of intercurrent disease. CONCLUSION: The primary treatment of choice for scrotal EMPD is radical excision. Precise, histological examination before and during the operation is of crucial importance. The positive excisal margins are one of the key causes of local recurrence, and the involvement of dermis by Pagets cells may suggest possible metastasis. Scrotal EMPD tends to occur as a slowly growing lesion, mainly in the elderly, and has a good prognosis in cases of non-invasion. Otherwise the prognosis is poor.

Aged↗
PubMed2005

[Regulation of expression of pituitary tumor transforming gene 1 (PTTG1) by androgen in prostate cancer].

OBJECTIVE: To identify the androgen-responsive genes in prostate and screen the molecular targets for further studying human prostate cancer. METHODS: The potential androgen-responsive gene pituitary tumor transforming gene 1 (PTTG1) was selected which had been previously screened by cDNA microarray in rat prostate and its mRNA level was detected by Northern blot in the castrated rat prostate with and without replacement of Mibolerone. Immunohistochemistry was performed to determine the expression and location of PTTG1 in human prostate tissues. Then human androgen-dependent prostate cancer cells LNCaP were used as a model to study the regulation of PTTG1 by Mibolerone. RESULTS: PTTG1 mRNA was hardly detectable in the prostate of 7-day castrated rats, while it was up-regulated dramatically in the prostate of 7-day castrated rats treated with Mibolerone for 2 days. It was showed that high expression of PTTG1 was localized to the epithelial cells of human prostate cancer but not to the stromal cells with Immunohistochemistry. Northern blot analysis indicated that LNCaP cells treated with 0.1 nmol/L Mibolerone for 2 days led to the high PTTG1 mRNA expression. The basic expression of PTTG1 in human androgen-independent prostate cancer cell lines PC3 or DU145 was even higher than that in the human androgen-dependent prostate cancer cells LNCaP treated with Mibolerone. CONCLUSION: Androgen can up-regulate the PTTG1 expression in castrated rat prostate and human prostate cancer cell LNCaP. It suggests that PTTG1 is potential to play an important role in human prostate cancer progression.

Adenocarcinoma↗
PubMed2005

[Ultrasound guided percutaneous puncture and sclerotherapy with alcohol for peripelvic cysts].

OBJECTIVE: To summarize the experience of ultrasound guided percutaneous aspiration and sclerotherapy for peripelvic cysts and investigate the clinical effect. METHODS: A total of 169 cases of peripelvic cyst patients were evaluated, of whom 36 cases (21.3%) had hydronephrosis secondary to peripelvic cysts, 8 cases (4.7%) had renal calculus. All patients underwent ultrasound and intravenous phelography (IVP) examination, 59 patients also had CT scan. Hydatid fluid was analyzed by amine test. Percutaneous aspiration was guided by ultrasound, 95% alcohol was used to sclerosis the peripelvic cysts when amine test was negative or positive but did not have communication with pelvis through opacification. Ultrasound were done at 1, 3, 6 months and every 1 year thereafter, follow-up period were 6 months to 5 years. RESULTS: One hundred and sixty-five peripelvic cysts (97.6%) were cured by once sclerotherapy, the diameter of another 4 cases (2.4%) diminished to less than 1.5 cm by once sclerotherapy. Thirty-six cases of hydronephrosis were all resolved after sclerotherapy. Eight cases had renal calculus, of whom 4 cases underwent extracorporeal shockwave lithotripsy, 2 cases underwent percutaneous nephrolithotomy, and 2 cases did not treat the stone. Five patients had gross hematuria after aspiration, but all diminished in 3-5 d. CONCLUSION: Ultrasound guided percutaneous aspiration and sclerotherapy for peripelvic cysts had the superiority of safety, effectiveness micro-invasion and low complication.

Adolescent↗
PubMed2005

[Polymorphism of metabolic gene and genetic susceptibility to prostate cancer].

OBJECTIVE: To study the possible relationship between the single nucleotide polymorphism (SNP) of cytochrome P-450 CYP1A1 (CYP1A1) m1, m2 and GSTM1 [null] genotype and genetic susceptibility to prostate cancer (PC). METHODS: Eighty-three PC patients and 115 age-matched healthy controls were enrolled in this study. All DNA samples from peripheral blood were genotyped for genetic polymorphisms of CYP1A1 and GSTM1 genes by genechip technique. RESULTS: There was a significant difference in the frequency of GSTM1 [null] genotype in PC cases (57.8%) compared to healthy controls (41.7%) (chi(2) = 4.99, P = 0.025). Individuals with the GSTM1 [null] genotype demonstrated increased risk (OR = 1.9, 95% CI = 1.10-1.34). The frequency of the GSTM1 [null] genotype was also higher in patients with advanced stage or high grade disease. There were no significant differences in the frequent distribution of two locate of CYP1A1 polymorphisms between prostate cancer patients and healthy controls (P > 0.05). CONCLUSIONS: GSTM1 [null] genotype may be linked to prostate cancer risk in Chinese population. GSTM1 [null] genotype was also related to the stage and grade, which may be helpful in determining the risk of locally disease and advanced PC.

Aged↗
PubMed2005

[Shape-memory alloy net-like stent for the management of ureteral stricture: a long-term follow-up report].

OBJECTIVE: To investigate the long-term outcome of treatment of ureteral stricture with shape-memory alloy net-like stent. METHODS: Nickel-titanium shape-memory alloy net-like stent was used to treat 9 patients with ureteral stricture, 4 males and 5 females, aged 41 (29-63), with the length of ureteral stricture of 1.0-4.0 cm, the etiology being radical operation for rectal carcinoma in 2 cases, chronic inflammation in 3 case, and operation for benign diseases in 4 cases. A total of 10 stents were inserted under spinal anesthesia. The mean follow-up time was 27.2 months (5-96 months). RESULTS: Ureteral obstruction was relieved in 7 cases (77.8%) with the relief or disappearance of hydronephrosis. The ureteral stents were blocked and re-obstruction appeared in 2 cases within 5-6 months due to hyperplasia of fibrous tissue. One of the cases underwent removal of stent and the other case underwent insertion of double-J with improvement of renal function. No radiological evidence of migration of stent and encrustation was found. CONCLUSION: More tolerable and with less side-effect and lower re-stricture rate, shape-memory alloy stent is better then Double-J in treatment of ureteral obstruction.

Adult↗